Cargando…
Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements
BACKGROUND: When use of a single antiseizure medication (ASM) fails to induce seizure remission, add-on therapy is justified. Perampanel (PER) is approved in Europe as adjunctive therapy for focal, focal to bilateral tonic-clonic seizures and generalized tonic-clonic seizures. Aim of the study was t...
Autores principales: | Bonanni, Paolo, Gambardella, Antonio, Tinuper, Paolo, Acone, Benedetto, Perucca, Emilio, Coppola, Giangennaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549193/ https://www.ncbi.nlm.nih.gov/pubmed/34702211 http://dx.doi.org/10.1186/s12883-021-02450-y |
Ejemplares similares
-
Correction: Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements
por: Bonanni, Paolo, et al.
Publicado: (2022) -
Current role of perampanel in pediatric epilepsy
por: De Liso, Paola, et al.
Publicado: (2017) -
Add-on perampanel in Lance–Adams syndrome
por: Steinhoff, Bernhard J., et al.
Publicado: (2016) -
Effectiveness of perampanel as the only add‐on: Retrospective, multicenter, observational real‐life study on epilepsy patients
por: Gasparini, Sara, et al.
Publicado: (2022) -
The 50th anniversary of the Italian League against epilepsy (Lega Italiana Contro l’Epilessia)()
por: Tassi, Laura, et al.
Publicado: (2022)